Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 2/2018

01-04-2018 | Original Article

Molecular Alterations and Expression Dynamics of LATS1 and LATS2 Genes in Non-Small-Cell Lung Carcinoma

Authors: Showkat A. Malik, Mosin S. Khan, Majeed Dar, Mahboob Ul Hussain, Mohammad A. Shah, Sheikh M. Shafi, Syed Mudassar

Published in: Pathology & Oncology Research | Issue 2/2018

Login to get access

Abstract

Large tumor suppressor (LATS) is an important member of the Hippo pathway which can regulate organ size and cell proliferation. However, very little is known about the expression and clinical significance of LATS in lung cancer especially from this part of the world. We elucidated the frequency of LATS1 &LATS2 promoter hypermethylation (by methylation-specific PCR) and expression (by real-time PCR) in sixty nine (n = 69) Non-Small Cell Lung Cancer (NSCLC) patients and their corresponding normal lung tissue samples. We found promoter hypermethylation frequencies of LATS1 & LATS1to be 66.66% (46/69) and 71% (49/69) in NSCLC tissues. Decreased LATS1 & LATS2 mRNA expression was found in 55% and 66.66% of NSCLC patients. The LATS1 mRNA expression was significantly higher in normal lung tissues. Also, the mRNA levels of LATS1 and LATS2 NSCLC tissues with hypermethylation were significantly lower. Multivariable analysis confirmed that LATS1 under expression increased the hazard of death after adjusting for other clinicopathological factors. Importantly, the loss of LATS1 mRNA expression was associated with overall short survival. LATS1 is an independent prognostic factor and may play an important role in NSCLC progression and may serve as a novel therapeutic target of NSCLC.
Literature
1.
2.
3.
Travis LB, Gospodarowicz M, Curtis RE et al (2002) Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 94:182–192CrossRefPubMed
4.
O'Mahony D, Kummar S, Gutierrez ME (2005) Non-small-cell lung cancer vaccine therapy: a concise review. J Clin Oncol 23:9022–9028CrossRefPubMed
5.
Nanda KA (2001) Consolidated report of the population based cancer registries, incidence & distribution of cancer, 1990–1996. Indian Council of Medical research, National Cancer Registry Program, New Delhi
6.
Pandith AA, Siddiqi MA (2012) Burden of cancers in the valley of Kashmir: 5Year epidemiological study reveals a different scenario. Tumor Biol 33:1629–1637CrossRef
7.
Zheng T, Wang J, Jiang H, Liu L (2011) Hippo signaling in oval cells and hepato-carcinogenesis. Cancer Lett 302:91–99CrossRefPubMed
8.
Halder G, Johnson RL (2011) Development 138:9–22
9.
Xia H, Qi H, Li Y, Pei J, Barton J, Blackstad M, Xu T, Tao W (2002) LATS1 tumor suppressor regulates G2/M transition and apoptosis. Oncogene 21:1233–1241CrossRefPubMed
10.
Tao W, Zhang S, Turenchalk GS et al (1999) Human homologue of the Drosophila melanogaster LATS tumour suppressor modulates CDC2 activity. Nat Genet 21:177–181CrossRefPubMed
11.
12.
Hisaoka M, Tanaka A, Hashimoto H (2002) Molecular alterations of h-warts/LATS1 tumor suppressor in human soft tissue sarcoma. Lab Investig 82:1427–1435CrossRefPubMed
13.
Matallanas D, Romano D et al (2007) RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell 27:962–975CrossRefPubMedPubMedCentral
14.
McPherson JP, Tamblyn L, Elia A et al (2004) LATS2/Kpm is required for embryonic development, proliferation control and genomic integrity. EMBO J 23:3677–3688CrossRefPubMedPubMedCentral
15.
Yabuta N, Okada N, Ito A et al (2007) Lats2 is an essential mitotic regulator required for the coordination of cell division. J Biol Chem 282:19259–19271CrossRefPubMed
16.
Ke H, Pei J, Ni Z, Xia H, Qi H, Woods T, Kelekar A, Tao W (2004) Putative tumor suppressor LATS2 induces apoptosis through down-regulation of Bcl-2 and Bcl-x(L). Exp Cell Res 298:329–338CrossRefPubMed
17.
Jiang Z, Li X, Hu J, Zhou W, Jiang Y, Li G, Lu D (2006) Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res 56:450–458CrossRefPubMed
18.
Jiménez-Velasco A, Román-Gómez J et al (2005) Down-regulation of the large tumor suppressor 2 (LATS/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia. Leukemia 19:2347–2350CrossRefPubMed
19.
Sasaki H, Hikosaka Y, Kawano O, Yano M, Fujii Y (2010) Hypermethylation of thelargetumor suppressor genes in Japanese lung cancer. Oncol Lett 1:303–307CrossRefPubMedPubMedCentral
20.
Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, Noguchi S (2005) Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 11:1380–1385CrossRefPubMed
21.
Bao Y, Hata Y, Ikeda M, Withanage K (2011) Mammalian hippo pathway: from development to cancer and beyond. J Biochem 149:361–379CrossRefPubMed
22.
Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad Sci USA 93:9821–9826CrossRef
23.
Steinmann K, Sandner A, Schagdarsurengin U, Dammann RH (2009) Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep 22:1519–1526PubMed
24.
Xu-Yng L, Xiu-Peng Z, Jun-Hua W, Xue-Shan Q, En-Hua W (2014) Expression of LATS1 contribute to good prognosis and can negatively regulate YAP oncoprotein in non-small cell lung cancer. Tumor Biol 35:6435–6443CrossRef
25.
Tianhai J, Dan L, Wei S, Wensheng Y, Haiqiao W, Xiuwu B (2012) Decreased exoression of LATS1 is correlated with the progression and prognosis of glioma. J Exp Clin Cancer Res 31:67–75CrossRef
26.
Wierzbicki PM, Adrych K, Kartanowicz D et al (2013) Underexpression of LATS1 TSG in colorectal cancer is associated with promoter hypermethylation. World J Gastroenterol 19:4363–4373CrossRefPubMedPubMedCentral
27.
Zhou G-X, Xiao-Yu L, Qi Z et al (2013) Effects of the hippo signaling pathway in human gastric cancer. Asian Pac J Cancer Prev 14:5199–5205CrossRefPubMed
28.
Xia H, Qi H, Li Y, Pei J, Barton J, Blackstad M, Xu T, Tao W (2002) LATS1 tumor suppressor regulates G2/M transition and apoptosis. Oncogene 21:1233–1241CrossRefPubMed
29.
Yang X, Li DM, Chen W, Xu T (2001) Human homologue of Drosophila LATS, negatively regulate growth by inducing G(2)M arrest or apoptosis. Oncogene 20:6516–6523CrossRefPubMed
30.
31.
Luo SY, Sit KY, Sihoe AD, Suen WS et al (2014) Abberant large tumor suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas. Lung Cancer 85:282–292CrossRefPubMedPubMedCentral
32.
Yu T, Bachman J, Lai ZC (2013) Evidence for a tumor suppressor role forthe large tumor suppressor genes LATS1 and LATS2 in humancancer. Genetics 195:1193–1196CrossRefPubMedPubMedCentral
33.
Ishizaki K, Fujimoto J, Kumimoto H et al (2002) Frequent polymorphic changes but rare tumor specific mutations of the LATS2 gene on 13q11-12 in esophageal squamous cell carcinoma. Int J Oncol 21:1053–1057PubMed
Metadata
Title
Molecular Alterations and Expression Dynamics of LATS1 and LATS2 Genes in Non-Small-Cell Lung Carcinoma
Authors
Showkat A. Malik
Mosin S. Khan
Majeed Dar
Mahboob Ul Hussain
Mohammad A. Shah
Sheikh M. Shafi
Syed Mudassar
Publication date
01-04-2018
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2018
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-017-0225-3

Other articles of this Issue 2/2018

Pathology & Oncology Research 2/2018 Go to the issue

Original Article

XPC Polymorphism and Risk for Lung Cancer in North Indian Patients Treated with Platinum Based Chemotherapy and Its Association with Clinical Outcomes

Research

RETRACTED ARTICLE: Impact of Toll-Like Receptors 2/3/4/9, IL-1-α/β and TNF-α Polymorphisms in Cervical Cancer Susceptibility in Tunisia

Original Article

Ki-67 and Cell Cycle Regulators p53, p63 and cyclinD1 as Prognostic Markers for Recurrence/ Progression of Bladder Urothelial Carcinoma

Original Article

Expression of Hypoxia-Associated Protein HIF-1α in Follicular Thyroid Cancer is Associated with Distant Metastasis

Erratum

Erratum to: Entangling Relation of Micro RNA-let7, miRNA-200 and miRNA-125 with Various Cancers

Original Article

Association between Level of Tumor Markers and Development of VTE in Patients with Pancreatic, Colorectal and Ovarian Ca: Retrospective Case- Control Study in Two Community Hospitals
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits